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OBJECTIVES: Pharmacotherapy is a major cost driver in venous thromboembolism
(VTE) treatment. Analyses of drug utilization and impact of pharmaceutical policy
are impeded by complicated rules of reimbursement, accessibility of data, changes
of prices and reference prices. The goal of this study was to critically assess utili-
zation and costs of reimbursed low-molecular weight heparins (LMWH) and vita-
min K antagonists (VKA) used on outpatient basis in Poland. METHODS: Reim-
bursement records of Silesian Provincial Division of National Health Fund (NHF)
were searched for detailed data on consumption of LMWH and VKA (FY 2009; about
4.646.000 insurees). Perspectives of public payer and patient were applied.
RESULTS: Market of antithrombotics was dominated by LMWH (97% of value, 98%
of reimbursement, 85% of packages number). Reimbursement constituted 94% of
LMWH value and 73% of VKA value. Daily cost of VTE pharmacotherapy with
LMWH was higher than with VKA (234 times for NHF, 42 times for patients). Within
groups of both LMWH and VKA reimbursement of daily doses of particular drugs
was changing in reverse manner than level of patient co-payment. Using warfarin
instead of acenocoumarol was more expensive for NHF by 147%, while for patients
cheaper by 25%. Using enoxaparin instead of nadroparin was for NHF more expen-
sive by 29%, but for patients less expensive by 15%. Using dalteparin instead of
nadroparin was even more expensive for NHF (by 46%), while for patients even
more cheap (by 23%). CONCLUSIONS: Market of reimbursed antithrombotic drugs
was dominated by LMWH. Pharmaceutical policy in Poland was not promoting
usage of less expensive therapeutic options within groups of LMWH and VKA.
Current implementation of new reimbursement law should be accompanied by
careful monitoring of impact, which it brings for rationalization of health policy.
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OBJECTIVES: Antithrombotic therapy with oral anticoagulants (vitamin K antago-
nists, VKAs) or antiplatelets (APs) is used to reduce stroke risk in patients with atrial
fibrillation (AF). This study reports on real-life prescription of VKAs and persistence
rates amongst AF patients in France and Spain. METHODS: A multicentre, retro-
spective, observational study was conducted using 2008–9 data from Longitudinal
Patient Databases (LPD©, Cegedim) of 1,200 and 300 general practitioners in France
and Spain, respectively. Patients with a diagnosis of AF during the study were
included and were considered to be receiving VKAs if they had 1 prescription
during the one-year follow-up. Persistence was defined as continuous use with
periods of 60 days interruption allowed. Persistence was assessed in newly diag-
nosed AF patients. RESULTS: In total, 11,355 and 2,924 AF patients were identified
in France and Spain, respectively. In France, VKAs were prescribed to 64% of pa-
tients (54% VKA only, 9% VKAAP) and 32% of eligible patients (CHADS2 stroke risk
score 2) did not receive anticoagulation. 15% of patients received no antithrom-
botic therapy. VKA persistence was 64% and 45% at 6 and 12 months. In Spain,
VKAs were prescribed to 52% of patients (44% VKA only, 8% VKAAP); 41% of
eligible patients did not receive anticoagulation. 16% of patients received no anti-
thrombotic therapy. VKA persistence was 60% and 38% at 6 and 12 months. In
France, univariate analyses showed anaemia, number of co-medications, hyper-
tension, BMI 25–30 kg/m2, age 75–84 years and age 85 years to be significant
negative predictors of persistence (p0.036 for all); prior myocardial infarction
(p0.079) was a non-significant negative predictor of persistence. CONCLUSIONS:
Prescription and persistence patterns in France and Spain show suboptimal adher-
ence to treatment guidelines and VKA therapy in both countries after both 6 and 12
months, suggesting that these AF patients remain at risk of stroke.
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OBJECTIVES: To evaluate colesevelam treatment persistence and associated
factors. METHODS: In this retrospective study, patients with hyperlipidemia (HL)
diagnosis were identified through electronic health records, who were 18 years
old, had an initial order for colesevelam between January 2004 and December 2011,
an LDL-C value within 3 months of the initial order date (baseline), and12 months
of LDL-C follow-up. Colesevelam treatment persistence was defined a priori as no
order gap 30 days. Multivariate stepwise logistic regression was performed to
assess clinical and patient-level factors associated with 12 months of co-
lesevelam treatment persistence. Adjusted odds ratios (OR) and corresponding 95%
confidence intervals (CIs) were calculated. A p-value 0.05 was considered statis-
tically significant. RESULTS: A total of 971 patients met the predefined inclusion
criteria, of which 48.2% had12 months of persistent treatment. Multivariate anal-
ysis showed that female sex (OR: 0.68; 95% CI: 0.53, 0.88; p0.004) and concurrent
insulin therapy (0.65; 0.46, 0.94; p0.021) were associated with a lower odds of
having 12 months colesevelam treatment persistence, whereas an increased
number of concomitant medications (1.09; 1.01, 1.19; p0.023) and concurrent in-
testinal cholesterol absorption inhibitor therapy (1.51; 1.08, 2.11; p0.016) was as-
sociated with a greater odds of having 12 months treatment persistence.
CONCLUSIONS: Several factors were significantly associated with colesevelam
treatment persistence among patients with HL in an integrated health system. In
particular, concomitant medication was associated with better treatment persis-
tence; these data may assist in optimizing therapy regimens for lipid management.
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OBJECTIVES: Dyslipidemia is a common disease that may lead to undesired car-
diovascular outcomes. We evaluated the LDL-c lowering drug use for patients at
three levels of risk defined by ATP III guidelines. METHODS: Three cohorts were
identified according to ATP III risk classification: high riskCHD or CHD equivalent
(HR); moderate risk2 risk factors (MR); low risk0-1 risk factor (LRIt’s recom-
mended that patient with these risk levels should receive the treatment if LDL was
greater than 130, 160 and 190 mg/dL, respectively. All patients were required to
have 6-month continuous health insurance coverage as ascertainment period and
LDL lowering drug use was evaluated in the subsequent two years using the US
Impact insurance claims database. RESULTS: We identified 9,866 HR, 17,539 MR
and 14,975 LR patients from 2006 to 2008. Compared with LR patients during
6-month baseline, HR and MR patients were older (mean age of 59, 59 versus 49
years), visited a cardiologist more often (46.9%, 12.2% vs 4.5%), had more hyperten-
sion (80.0%, 90.8% vs 10.8%) and diabetes (19.3%, 14.6% vs 4.6%), and incurred
higher mean health care expenditures ($8,803, $3,419 vs $1,966). For all three co-
horts, the majority of patients did not have lipid lowering medications dispensed
within 2 years (57.1%, 54.4% and 58.2%, respectively). For patients who did, lower
dose statins was the most commonly dispensed (52.0%, 52.6% and 51.4%, respec-
tively). Overall, the medication possession rate is low (0.6) and a relatively low
percentage of patients changed their medications. CONCLUSIONS: Despite ATP
recommendations for treatment, the majority of the patients at all risk levels were
not using lipid lowering medications two years after ascertainment of excess LDL
level. Among patients who obtained the medications, lower dose statins were most
commonly used. Furthermore, medication adherence in the treated patients was
suboptimal, suggesting remaining unmet therapeutic needs in this patient popu-
lation.
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OBJECTIVES: Reaching target dose of neurohormonal blockade drugs is crucial for
health outcomes in chronic heart failure (CHF). Our aim was to present dosage
analysis for CHF therapies. Our calculation was presented on the basis of represen-
tative patient attendance data from the National Health Insurance Fund Adminis-
tration (NHIFA) in Hungary.METHODS:NHIFA database uniquely contains detailed
provision data (medicine, out- and inpatient services) from the whole Hungarian
population of 10 million. All financed health care providers use the same report
structure and reported data are strictly validated. Our retrospective analyses in-
cluded data of 2004-2010 for all patients with chronic heart failure (ICD code I50) as
main diagnosis. Rate of therapy and dosage pattern were analysed on the basis of
prescription data. Real world dose of therapy was estimated as filled volume per
time between prescription fill. Estimated dose per day was aggregated on half year
basis from the first medicine record. On the basis of histological data titration
patterns were analysed as well. RESULTS: Merely 80% of CHF patients is treated
with adequate therapy. Results for dosage patterns showed, that patients are not
reaching target dose in practice, and titration process is suboptimal as well.
CONCLUSIONS: Patient and disease management program of CHF patients could
improve health outcomes by enhance treatment effectiveness.
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OBJECTIVES: Statins are the treatment of choice for lowering LDL-C levels and
reducing cardiovascular events. Statins are given to people with at least 20% risk of
having a major vascular event within 10 years. They reduce risk of serious vascular
events by 21 percent. Currently available statins in Slovakia are lovastatin, simva-
statin, fluvastatin, atorvastatin, rosuvastatin. METHODS: Data were abstracted
from Slovak Institute for Drug Control. Key data for analysis including the number
of medicine packages and financial expenditures are provided to SIDC by
wholesalers. RESULTS: The highest consumption of statins within years 2008-2012
was observed in 2010 with total expenditures of 25.9 mil. € and with 3.5 prescribed
packages. Financial expenditures rose gradually from 22.9 mil. € in 2008 to 25.9 mil.
€ in 2010 and subsequently declined to 25.3 mil. € in 2011. In first quartal of 2012 the
downward trend continues with estimated annual decrease to 22.9 millions €.
Consumption expressed in number of packages flactuated from 2.8 mil. in 2008 to
3.3 in 2011, with expected downturn to 3.1 in 2012. Significant increase in number
of issued packages was noted between 2008 and 2009, while financial expenditures
exceeded their growth between 2009 and 2010. The most frequently used statin in
Slovakia is atorvastatin (65% in 2011) followed by simvastatin (21% in 2011). The
expenditures of rosuvastatin almost trippled in both financial and physical units
within 2008-2011. The Lowest consumption showed lovastatin (0.9% in 2011).
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